Hypogammaglobulinemia in Multiple Sclerosis Patients Receiving Disease-Modifying Immunomodulatory Agents

被引：0
|
作者：
Tsao, Lulu [1 ]
Otani, Iris M. [2 ]
Bove, Riley [3 ]
机构：
[1] UCSF, Dept Med, San Francisco, CA USA
[2] UCSF, Dept Internal Med, Div Allergy & Immunol, San Francisco, CA USA
[3] UCSF, Dept Neurol, San Francisco, CA USA
来源：
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY | 2019年 / 143卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
49
引用
收藏
页码：AB17 / AB17
页数：1
相关论文
共 50 条
  • [31] Persistence to oral disease-modifying therapies in multiple sclerosis patients
    Lattanzi, Simona
    Danni, Maura
    Taffi, Ruja
    Cerqua, Raffaella
    Carlini, Giulia
    Pulcini, Alessandra
    Provinciali, Leandro
    Silvestrini, Mauro
    JOURNAL OF NEUROLOGY, 2017, 264 (11) : 2325 - 2329
  • [32] Factors associated with the initiation of high-efficacy disease-modifying agents over moderate-efficacy disease-modifying agents in multiple sclerosis
    Li, Jieni
    Hutton, George J.
    Varisco, Tyler J.
    Lin, Ying
    Essien, Ekere J.
    Aparasu, Rajender R.
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2024, 91
  • [33] EFFECTIVENESS OF COVID-19 VACCINES IN MULTIPLE SCLEROSIS PATIENTS RECEIVING DISEASE-MODIFYING THERAPIES IN ENGLAND
    Garjani, Afagh
    Patel, Sameer
    Law, Graham R.
    Bharkhada, Dhiren
    Rashid, Waqar
    Coles, Alasdair
    Evangelou, Nikos
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2022, 93 (09):
  • [34] COVID-19 vaccination in patients with multiple sclerosis receiving disease-modifying therapies: pragmatic issues
    Chirap-Mitulschi, Ioan-Alexandru
    Ghimus, Constantin
    Chirap-Mitulschi, Andreea Raluca
    Antoniu, Sabina Antonela
    Dragomir, Raluca
    DRUGS OF TODAY, 2022, 58 (12) : 605 - 620
  • [35] Productivity Loss and Associated Costs Among Employed Patients Receiving Disease-Modifying Treatment for Multiple Sclerosis
    Machaon Bonafede
    Rina Mehta
    Gilwan Kim
    Ila Sruti
    Marc Tian
    Corey Pelletier
    Neil Goldfarb
    PharmacoEconomics - Open, 2021, 5 : 23 - 34
  • [36] Productivity Loss and Associated Costs Among Employed Patients Receiving Disease-Modifying Treatment for Multiple Sclerosis
    Bonafede, Machaon
    Mehta, Rina
    Kim, Gilwan
    Sruti, Ila
    Tian, Marc
    Pelletier, Corey
    Goldfarb, Neil
    PHARMACOECONOMICS-OPEN, 2021, 5 (01) : 23 - 34
  • [37] Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis
    Zivadinov, R.
    Reder, A. T.
    Filippi, M.
    Minagar, A.
    Stueve, O.
    Lassmann, H.
    Racke, M. K.
    Dwyer, M. G.
    Frohman, E. M.
    Khan, O.
    NEUROLOGY, 2008, 71 (02) : 136 - 144
  • [38] The use of disease-modifying agents in multiple sclerosis - by the Canadian Network of MS clinics
    O'Connor, Paul
    CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES, 2008, 35 (02) : 127 - 129
  • [39] The Cost of Multiple Sclerosis and the Cost Effectiveness of Disease-Modifying Agents in its Treatment
    Ceri J. Phillips
    CNS Drugs, 2004, 18 : 561 - 574
  • [40] The cost of multiple sclerosis and the cost effectiveness of disease-modifying agents in its treatment
    Phillips, CJ
    CNS DRUGS, 2004, 18 (09) : 561 - 574
12345